Gilead's Chances Peak Until GSK’s Response to the Competition Announcement Gilead’s new PreP drug, ‘Yeztugo’, is said to be reaching sales of $4.5 billion, if GSK doesn’t have anything to say about its Apretude medication. Gilead is strengthening its position in the...
BioVersys and Shionogi Joined Forces to Accelerate Research and Development Announcement BioVersys AG, a biopharmaceutical company known for its excellent research and development of antibacterial products for severe infections caused by multidrug-resistant (MDR) bacteria, has signed an exclusiv...
Rinri’s Clinical Trial Application, a First Approval of the Month Image Credits: Hearing Health & Technology Matters Announcement Rinri Therapeutics, a global company aiming to bring a transformation and development in sensorineural hearing loss (SNHL) with regenerative cell therapy, ...
Another Innovation to be Launched at ENDO 2025 Image Credits: The Manila Times Announcement Crinetics Pharmaceuticals, Inc. is ready to showcase eight abstracts from its clinical development programs, and its oral presentations involve an investigational drug candidate, atumelnant, and PALSONIF...
MaxCyte ExPERT Platform in Japan Image Credits: Galveston Country Daily News Announcement The PHC corporation, a biomedical division subsidiary of PHC Holdings Corporation, has entered an agreement with MaxCyte Inc. for the distribution of the MaxCyte ExPERT platform in Japan. In June, Singapor...
A Clinical Collaboration to Fuel the Healthcare Market Image Credits: Seeking Alpha Announcement Summit Therapeutics Inc., a biopharmaceutical oncology company, and Revolution Medicines Inc., a leading clinical oncology company, have entered into a clinical collaboration. Revolution medicines m...
HUTCHMED Received Approval from China Image Credits: Sharecast Announcement HUTCHMED (China) Limited has received approval from the China National Medical Products Administration (NMPA) for its new drug application merging TAGRISSO® (osimertinib) and ORPATHYS® (savolitinib). The approva...
Riliprubart Received Orphan Drug Designation in Japan Image Credits: Western Slope Now Announcement The Japanese Ministry of Health, Labour and Welfare appointed riliprubart as an orphan drug designation. Riliprubart is a monoclonal antibody suppressing active C1s in the classical complement fo...
ESTEVE’s Agreement with Sanofi Image Credits: AInvest Announcement ESTEVE signed an agreement with Sanofi, a French multinational pharmaceutical and health-care company, to acquire Caprelsa® (vandetanib) rights in over 50 countries and more. It’s a treatment that applies to chil...
June Wrap-up with Approvals Image Credits: Biospace Approvals The FDA recently granted approvals for UroGen and RSV immunization. With the approval, Moderna expands mRNA RSV shot. On 13th June 2025, the FDA confirmed Moderna’s mRNA vaccine, mResvia, for respiratory syncytial virus, a solu...
